explore -WSS

explore

author：entertainment 2025-09-29 00:39:17 - browse：42

Portrait of Don Davis -- health policy coverage from STAT — U.S. Representative Don Davis (D-N.C.) Wikimedia Commons

WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s Medicare drug price negotiation program managed to find themselves a Democratic co-sponsor — even though every single Democrat in Congress in 2022 voted for the legislation.

They found their perfect candidate in Rep. Don Davis, a Democrat representing a North Carolina district that includes parts of the state’s Research Triangle. He came to Washington in 2023, so didn’t vote on the original law. He received donations in 2023 from the political action committees for Gilead, Astellas, Genentech, Bayer, Pfizer, Novo Nordisk, GSK, Bristol Myers Squibb, BIO, Amgen, Boehringer Ingelheim, Merck, AbbVie, and Eli Lilly.

“We must support the development of critical, life-sustaining medical treatments and cures,” Davis said in a written statement, and a spokesperson declined to elaborate. He is joined on the bill by Rep. Greg Murphy (R-N.C.) and Brett Guthrie (R-Ky.), the Energy and Commerce health subcommittee chairman.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： A strong 6.5

WSS

BridgeBio heart drug succeeds in pivotal study

Manchin plays down potential 3rd

Why you get paid to donate plasma but not blood

U.K. sequencing study surfaces new findings about tumor DNA

How a scoliosis diagnosis changed the life of one young dancer

Lack of darker skin in textbooks, journals harms patients of color

hotspot

explore

explore

Affirmative action in medical school literally saved lives

BridgeBio heart drug succeeds in pivotal study

Alkermes shareholders re

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Walensky prepares to leave CDC — and Congress — behind

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

ChatGPT in medicine: STAT answers readers' burning questions

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Trump demands the U.S. pay no more for drugs than other countries … again

Manchin plays down potential 3rd

leisure time

A look at other Americans who have crossed into North Korea over the years

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

FDA seeking to stop procedures at two unregulated stem cell clinics

BridgeBio heart drug succeeds in pivotal study

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

J&J to buy cancer drug developer Ambrx Biopharma

entertainment

explore

leisure time

knowledge